Oncology Data Advisor

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Don't forget to take the activity and claim your credit after the episode! Click here to take module 1 of the activity: bit.ly/3Y3ivHM

Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj

Read the full article at: https://oncdata.com/inav-daniel-king Pancreatic cancer remains one of oncology’s most challenging diseases—fast-moving, hard to detect early, and often diagnosed after curative options have narrowed. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Daniel King, Gastrointestinal Medical Oncologist at Northwell Health and co-inventor of iNav, an AI-enabled navigation platform designed to expedite diagnosis and treatment for patients with suspected pancreatic cancer.

Treatment for systemic mastocytosis (SM) has evolved fast—are your management strategies keeping up? Join Dr. Castells as she dives into the latest advances in SM therapy, including how and when to leverage tyrosine kinase inhibitors, and how to collaborate across specialties to tailor care that truly meets each patient’s needs. Packed with practical pearls and forward‑looking insights, this episode will help you elevate symptom control, safety, and quality of life for your patients. Listen now before this accredited activity expires on April 15! Click here to claim your CME/NCPD/AAPA credit: bit.ly/4cxzgAK

Systemic mastocytosis (SM) can hide in plain sight—are you catching it when it counts? In this case‑driven conversation, Dr. Mariana Castells breaks down the real-world diagnostic journey of SM, highlighting the subtle clues, surprising presentations, and essential criteria every oncology professional should have on their radar. Listen now and feel better equipped to recognize SM early, avoid common diagnostic pitfalls, and confidently guide patients toward the answers they need. Don’t miss your chance to earn credit—this episode expires April 15. Click here to claim your CME/NCPD/AAPA credit: bit.ly/42vUKJJ Click here to continue with this series and listen to Module 2:

Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs. Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making. Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next. Click the link to view the full activ

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-molecular-testing In the rapidly evolving landscape of modern oncology, molecular testing has emerged as one of the most powerful tools for personalizing patient care. However, this explosion of data has also created a "molecular testing chaos" that can overwhelm even the most seasoned clinicians. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, to discuss whether we are over-testing, under-testing, or simply testing the wrong things at the wrong time. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-financial-toxicity In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option? They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care. The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and ske

Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms. i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient. Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity. Click the link to complete module 1 and claim your free credit: bit.ly/4iYmYD2

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available. You can catch the live session on either of these dates: Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0 Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies. The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best! Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRil Monday, February 2 at 7:00 pm ET - bit.ly/495gnEd

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 2 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 2: bit.ly/43VoFNP

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

Read the full article at: https://oncdata.com/travis-osterman-ai-informatics In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Travis Osterman, Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center, about the evolving role of health informatics in oncology. Their conversation spans training pathways, precision oncology, data standards, AI integrations, and the strategies to promote adoption in both academic and community practices.

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets. Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs! Click the link to claim your CE credit:

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool.